biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Protalix

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Feb 25, 2023 11:33am

72 Views

Post# 35305150

RE:RE:RE:RE:RE:Protalix

prophetoffactz wrote: ""Also, the J&J multi-product option appears to have progressed."

Progressed into what exactly?"

There was no replay of the AGM that I'm aware of but I believe Rathjen said the J&J deal was extended, expanded, and a small milestone payment to BTI was made.

"Rathjen said the J&J deal was extended, expanded, and a small milestone payment to BTI was made."

Don't know the date of what Rathjen said, allegedly. So does it mean that the J&J deal is still alive?

G1945V

<< Previous

Bullboard Posts

Next >>

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload